补体激活可预测系统性红斑狼疮和/或抗磷脂抗体患者的妊娠不良结局
PROMISSE研究纳入妊娠不足12周的系统性红斑狼疮(SLE)和/或抗磷脂(aPL)抗体孕妇487例及健康对照孕妇204例,每月随访评估妊娠不良结局(APO)。20.5%的SLE和/或aPL孕妇发生APO;孕12-15周时Bb和sC5b-9水平在发生APO者中显著升高并持续至31周,校正人口学和临床危险因素后仍与APO显著相关,在aPL阳性患者中Bb的关联更强。
要点
- SLE和/或aPL抗体孕妇APO发生率为20.5%。
- 孕12-15周Bb和sC5b-9升高与APO显著相关(ORadj分别为1.41和1.37每SD增加)。
- aPL阳性患者中孕12-15周Bb与APO关联更强(ORadj=2.01每SD增加)。
核心结论
- 在SLE和/或aPL抗体孕妇中,妊娠早期可检测到的Bb和sC5b-9升高对APO有强烈预测作用,支持补体激活(尤其是旁路途径)参与APO的发生。
研究设计与样本
- PROMISSE研究为前瞻性队列,纳入妊娠不足12周的系统性红斑狼疮(SLE)和/或抗磷脂(aPL)抗体孕妇487例及健康对照孕妇204例,每月随访评估。
主要发现
- SLE和/或aPL孕妇中APO发生率为20.5%。
- 孕12-15周时,发生APO的患者Bb和sC5b-9水平显著高于结局正常者,并持续升高至31周。
- 无APO的SLE和/或aPL患者Bb和sC5b-9水平也显著高于健康对照。
- 校正PROMISSE中APO的人口学和临床危险因素后,孕12-15周Bb与APO相关(ORadj=1.41每SD增加;95%CI 1.06至1.89;P=0.019),sC5b-9与APO相关(ORadj=1.37每SD增加;95%CI 1.05至1.80;P=0.022)。
- 在aPL阳性患者(n=161)中,孕12-15周Bb与APO的关联更强(ORadj=2.01每SD增加;95%CI 1.16至3.49;P=0.013)。
关键数值与推荐
- APO定义:胎儿/新生儿死亡、因胎盘功能不全或子痫前期导致的36周前早产和/或生长受限低于第5百分位。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. METHODS: The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly. APOs were: fetal/neonatal death, preterm delivery <36 weeks because of placental insufficiency or preeclampsia and/or growth restriction <5th percentile. Complement activation products were measured on serial blood samples obtained at each monthly visit. RESULTS: APO occurred in 20.5% of SLE and/or aPL pregnancies. As early as 12-15 weeks, levels of Bb and sC5b-9 were significantly higher in patients with APOs and remained elevated through 31 weeks compared with those with normal outcomes. Moreover, Bb and sC5b-9 were significantly higher in patients with SLE and/or aPL without APOs compared with healthy controls. In logistic regression analyses, Bb and sC5b-9 at 12-15 weeks remained significantly associated with APO (ORadj=1.41 per SD increase; 95% CI 1.06 to 1.89; P=0.019 and ORadj=1.37 per SD increase; 95% CI 1.05 to 1.80; P=0.022, respectively) after controlling for demographic and clinical risk factors for APOs in PROMISSE. When analyses were restricted to patients with aPL (n=161), associations between Bb at 12-15 weeks and APOs became stronger (ORadj=2.01 per SD increase; 95% CI 1.16 to 3.49; P=0.013). CONCLUSION: In pregnant patients with SLE and/or aPL, increased Bb and sC5b-9 detectable early in pregnancy are strongly predictive of APOs and support activation of complement, particularly the alternative pathway, as a contributor to APOs.
引用
- Kim MY, Guerra MM, Kaplowitz E, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018. PMID: 29371202. doi:10.1136/annrheumdis-2017-212224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。